{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:01:44Z","timestamp":1788778904599,"version":"build-2803163510"},"reference-count":106,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["R01 GM123378"],"award-info":[{"award-number":["R01 GM123378"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["R01GM139752"],"award-info":[{"award-number":["R01GM139752"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["DP1AI158186"],"award-info":[{"award-number":["DP1AI158186"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201700059C"],"award-info":[{"award-number":["HHSN272201700059C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI147846"],"award-info":[{"award-number":["R01 AI147846"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1156262"],"award-info":[{"award-number":["OPP1156262"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001906","name":"Washington Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001906","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD032290"],"award-info":[{"award-number":["S10OD032290"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.xcrm.2022.100658","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T10:44:31Z","timestamp":1655203471000},"page":"100658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Immunization with a self-assembling nanoparticle vaccine displaying EBV gH\/gL protects humanized mice against lethal viral challenge"],"prefix":"10.1016","volume":"3","author":[{"given":"Harman","family":"Malhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah J.","family":"Homad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibhav","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Borst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Walkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suruchi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Moodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin E.","family":"Correnti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry L.","family":"Stoddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Veesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Pancera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2022.100658_bib1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","article-title":"The global landscape of EBV-associated tumors","volume":"9","author":"Shannon-Lowe","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2022.100658_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The immunology of Epstein-Barr virus-induced disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2022.100658_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/978-981-10-7230-7_22","article-title":"Vaccine development for Epstein-Barr virus","volume":"1045","author":"Cohen","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.xcrm.2022.100658_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.pathol.1.110304.100209","article-title":"Spectrum of Epstein-Barr virus-associated diseases","volume":"1","author":"Kutok","year":"2006","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.xcrm.2022.100658_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-9-38","article-title":"Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010","volume":"9","author":"Khan","year":"2014","journal-title":"Infect. Agents Cancer"},{"key":"10.1016\/j.xcrm.2022.100658_bib6","doi-asserted-by":"crossref","first-page":"107fs107","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr virus: an important vaccine target for cancer prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2022.100658_bib7","doi-asserted-by":"crossref","first-page":"e037505","DOI":"10.1136\/bmjopen-2020-037505","article-title":"Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990-2017","volume":"10","author":"Khan","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.xcrm.2022.100658_bib8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ana.21978","article-title":"Primary infection with the Epstein-Barr virus and risk of multiple sclerosis","volume":"67","author":"Levin","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2022.100658_bib9","doi-asserted-by":"crossref","first-page":"e12496","DOI":"10.1371\/journal.pone.0012496","article-title":"An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis","volume":"5","author":"Handel","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2022.100658_bib10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.20820","article-title":"Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis","volume":"59","author":"Thacker","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2022.100658_bib11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/1352458511408991","article-title":"Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel","volume":"17","author":"Munger","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.xcrm.2022.100658_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jbspin.2017.04.011","article-title":"Epstein-Barr virus and rheumatoid arthritis","volume":"85","author":"Balandraud","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.xcrm.2022.100658_bib13","doi-asserted-by":"crossref","first-page":"e1003220","DOI":"10.1371\/journal.ppat.1003220","article-title":"Increased CD8+ T\u00a0cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis","volume":"9","author":"Angelini","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.xcrm.2022.100658_bib14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100658_bib15","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1038\/d41586-018-07366-1","article-title":"Building a better lymphoma vaccine","volume":"563","author":"Ainsworth","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100658_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.it.2014.01.003","article-title":"Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory","volume":"35","author":"Rickinson","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2022.100658_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","article-title":"The structural basis of herpesvirus entry","volume":"19","author":"Connolly","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.xcrm.2022.100658_bib18","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1073\/pnas.0810530106","article-title":"Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B","volume":"106","author":"Backovic","year":"2009","journal-title":"Proc. Nat. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.xcrm.2022.100658_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/viro.2000.0531","article-title":"Epstein-Barr virus lacking glycoprotein gp85 cannot infect B cells and epithelial cells","volume":"276","author":"Oda","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2022.100658_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.coviro.2012.10.005","article-title":"Stuck in the middle: structural insights into the role of the gH\/gL heterodimer in herpesvirus entry","volume":"3","author":"Stampfer","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib21","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1128\/jvi.63.12.4998-5005.1989","article-title":"Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells","volume":"63","author":"Haddad","year":"1989","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.14348\/molcells.2016.0066","article-title":"Structural and mechanistic insights into the tropism of Epstein-Barr virus","volume":"39","author":"Mohl","year":"2016","journal-title":"Mol. Cell."},{"key":"10.1016\/j.xcrm.2022.100658_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nm830","article-title":"Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells","volume":"9","author":"Tugizov","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100658_bib24","doi-asserted-by":"crossref","first-page":"20464","DOI":"10.1073\/pnas.0907508106","article-title":"Fusion of epithelial cells by Epstein\u2013Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins \u03b1v\u03b26 or \u03b1v\u03b28","volume":"106","author":"Chesnokova","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.xcrm.2022.100658_bib25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41564-017-0081-7","article-title":"Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus","volume":"3","author":"Chen","year":"2018","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.xcrm.2022.100658_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41564-017-0080-8","article-title":"Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry","volume":"3","author":"Zhang","year":"2018","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.xcrm.2022.100658_bib27","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1038\/ncomms7240","article-title":"Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100658_bib28","doi-asserted-by":"crossref","first-page":"11036","DOI":"10.1073\/pnas.1513359112","article-title":"Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells","volume":"112","author":"Xiong","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.xcrm.2022.100658_bib29","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.1038\/s41467-020-19617-9","article-title":"Molecular basis of EphA2 recognition by gHgL from gammaherpesviruses","volume":"11","author":"Su","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100658_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0092-8674(87)90216-9","article-title":"Epstein-Barr virus gp350\/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis","volume":"50","author":"Tanner","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100658_bib31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.celrep.2013.01.023","article-title":"Human complement receptor type 1\/CD35 is an Epstein-Barr Virus receptor","volume":"3","author":"Ogembo","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2022.100658_bib32","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1128\/jvi.61.5.1416-1420.1987","article-title":"Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV\/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d","volume":"61","author":"Nemerow","year":"1987","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib33","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1128\/jvi.70.8.5557-5563.1996","article-title":"The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation","volume":"70","author":"Spriggs","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib34","doi-asserted-by":"crossref","first-page":"e1004309","DOI":"10.1371\/journal.ppat.1004309","article-title":"Assembly and architecture of the EBV B cell entry triggering complex","volume":"10","author":"Sathiyamoorthy","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.xcrm.2022.100658_bib35","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/JVI.74.5.2451-2454.2000","article-title":"Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor","volume":"74","author":"Haan","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib36","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.xcrm.2022.100658_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100658_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virol.2009.06.013","article-title":"Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay","volume":"391","author":"Sashihara","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2022.100658_bib39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/infdis\/125.4.403","article-title":"Infectious mononucleosis: appearance of neutralizing antibody to Epstein-Barr virus measured by inhibition of formation of lymphoblastoid cell lines","volume":"125","author":"Miller","year":"1972","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100658_bib40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1099\/0022-1317-17-2-233","article-title":"Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in\u00a0vitro","volume":"17","author":"Moss","year":"1972","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib41","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/jvi.43.2.730-736.1982","article-title":"Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in\u00a0vivo","volume":"43","author":"Thorley-Lawson","year":"1982","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virol.2009.07.025","article-title":"EBV-positive human sera contain antibodies against the EBV BMRF-2 protein","volume":"393","author":"Xiao","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2022.100658_bib43","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2022.100658_bib44","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1073\/pnas.77.5.2979","article-title":"Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen","volume":"77","author":"Hoffman","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.xcrm.2022.100658_bib45","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1128\/jvi.62.12.4452-4464.1988","article-title":"Soluble gp350\/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes","volume":"62","author":"Tanner","year":"1988","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2019.07.026","article-title":"Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes","volume":"536","author":"Mutsvunguma","year":"2019","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2022.100658_bib47","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/nsmb1161","article-title":"Structure of the Epstein-Barr virus major envelope glycoprotein","volume":"13","author":"Szakonyi","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.xcrm.2022.100658_bib48","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/JVI.74.14.6324-6332.2000","article-title":"Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells","volume":"74","author":"Molesworth","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib49","doi-asserted-by":"crossref","first-page":"9628","DOI":"10.1128\/JVI.00622-06","article-title":"Antibodies to gp350\/220 enhance the ability of Epstein-Barr virus to infect epithelial cells","volume":"80","author":"Turk","year":"2006","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib50","doi-asserted-by":"crossref","first-page":"100352","DOI":"10.1016\/j.xcrm.2021.100352","article-title":"Neutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model","volume":"2","author":"M\u00fche","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2022.100658_bib51","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100658_bib52","doi-asserted-by":"crossref","first-page":"B194","DOI":"10.1016\/j.vaccine.2012.09.041","article-title":"The need and challenges for development of an Epstein-Barr virus vaccine","volume":"31","author":"Cohen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2022.100658_bib53","doi-asserted-by":"crossref","first-page":"13214","DOI":"10.1128\/JVI.05580-11","article-title":"Fusion of Epstein-Barr virus with epithelial cells can be triggered by \u03b1v\u03b25 in addition to \u03b1v\u03b26 and \u03b1v\u03b28, and integrin binding triggers a conformational change in glycoproteins gHgL","volume":"85","author":"Chesnokova","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib54","doi-asserted-by":"crossref","first-page":"E8703","DOI":"10.1073\/pnas.1704661114","article-title":"Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies","volume":"114","author":"Sathiyamoorthy","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.xcrm.2022.100658_bib55","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","article-title":"An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein-Barr virus","volume":"48","author":"Snijder","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2022.100658_bib56","doi-asserted-by":"crossref","first-page":"13557","DOI":"10.1038\/ncomms13557","article-title":"Structural basis for Epstein-Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins","volume":"7","author":"Sathiyamoorthy","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100658_bib57","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1128\/jvi.69.7.3987-3994.1995","article-title":"The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells","volume":"69","author":"Li","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib58","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1038\/s41467-021-26912-6","article-title":"A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus","volume":"12","author":"Zhu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100658_bib59","doi-asserted-by":"crossref","first-page":"100033","DOI":"10.1016\/j.xcrm.2020.100033","article-title":"Neutralizing antibodies protect against oral transmission of lymphocryptovirus","volume":"1","author":"Singh","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2022.100658_bib60","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","article-title":"Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350","volume":"34","author":"Cui","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2022.100658_bib61","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41594-020-0397-5","article-title":"Engineering and functionalization of large circular tandem repeat protein nanoparticles","volume":"27","author":"Correnti","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.xcrm.2022.100658_bib62","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1128\/IAI.01369-07","article-title":"The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria","volume":"76","author":"Ogun","year":"2008","journal-title":"Infect. Immun."},{"key":"10.1016\/j.xcrm.2022.100658_bib63","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100658_bib64","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nature18010","article-title":"Design of a hyperstable 60-subunit protein dodecahedron. [corrected]","volume":"535","author":"Hsia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100658_bib65","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1093\/nar\/gkr706","article-title":"Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors","volume":"39","author":"Bandaranayake","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2022.100658_bib66","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/356347a0","article-title":"Epstein\u2013Barr virus infection and replication in a human epithelial cell system","volume":"356","author":"Li","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100658_bib67","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/pathogens9020116","article-title":"Animal models for Gammaherpesvirus infections: recent development in the analysis of virus-induced pathogenesis","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.xcrm.2022.100658_bib68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.coviro.2017.07.026","article-title":"Humanized mouse models for Epstein Barr virus infection","volume":"25","author":"M\u00fcnz","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.xcrm.2022.100658_bib69","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/vaccines9030285","article-title":"Immunization with Epstein\u2013Barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose EBV challenge","volume":"9","author":"Cui","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.xcrm.2022.100658_bib70","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virol.2021.06.006","article-title":"Epstein-Barr virus (EBV) hyperimmune globulin isolated from donors with high gp350 antibody titers protect humanized mice from challenge with EBV","volume":"561","author":"Kim","year":"2021","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2022.100658_bib71","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-04-709584","article-title":"A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production","volume":"129","author":"Yu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2022.100658_bib72","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1086\/590502","article-title":"A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses","volume":"198","author":"Yajima","year":"2008","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100658_bib73","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1086\/644644","article-title":"T cell-mediated control of Epstein-Barr virus infection in humanized mice","volume":"200","author":"Yajima","year":"2009","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100658_bib74","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","article-title":"Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses","volume":"20","author":"Kanekiyo","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2022.100658_bib75","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1016\/j.cell.2021.09.015","article-title":"Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines","volume":"184","author":"Walls","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100658_bib76","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","article-title":"Quadrivalent influenza nanoparticle vaccines induce broad protection","volume":"592","author":"Boyoglu-Barnum","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100658_bib77","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100658_bib78","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1038\/s41467-019-12080-1","article-title":"Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle","volume":"10","author":"Brouwer","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100658_bib79","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100658_bib80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41541-020-00274-4","article-title":"An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein","volume":"6","author":"Jel\u00ednkov\u00e1","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.xcrm.2022.100658_bib81","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1073\/pnas.1112648109","article-title":"Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction","volume":"109","author":"Moon","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.xcrm.2022.100658_bib82","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2022.100658_bib83","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/nmat3775","article-title":"Engineering synthetic vaccines using cues from natural immunity","volume":"12","author":"Irvine","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.xcrm.2022.100658_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2020.01.007","article-title":"Shaping humoral immunity to vaccines through antigen-displaying nanoparticles","volume":"65","author":"Irvine","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2022.100658_bib85","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41565-020-0719-0","article-title":"Role of nanoscale antigen organization on B-cell activation probed using DNA origami","volume":"15","author":"Veneziano","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.xcrm.2022.100658_bib86","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","article-title":"Multifaceted effects of antigen valency on B cell response composition and differentiation in\u00a0vivo","volume":"53","author":"Kato","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2022.100658_bib87","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a subunit COVID-19 vaccine to induce protective immunity","volume":"594","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100658_bib88","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fonc.2019.00104","article-title":"Progress in EBV vaccines","volume":"9","author":"van Zyl","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2022.100658_bib89","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/emm.2014.88","article-title":"Modeling EBV infection and pathogenesis in new-generation humanized mice","volume":"47","author":"Fujiwara","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xcrm.2022.100658_bib90","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1126\/science.276.5321.2030","article-title":"An animal model for acute and persistent Epstein-Barr virus infection","volume":"276","author":"Moghaddam","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100658_bib91","doi-asserted-by":"crossref","first-page":"8245","DOI":"10.1073\/pnas.95.14.8245","article-title":"Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells","volume":"95","author":"Delecluse","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.xcrm.2022.100658_bib92","doi-asserted-by":"crossref","first-page":"10618","DOI":"10.1038\/ncomms10618","article-title":"Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice","volume":"7","author":"Mcguire","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100658_bib93","doi-asserted-by":"crossref","first-page":"8815","DOI":"10.1073\/pnas.1404575111","article-title":"Single-particle EM reveals plasticity of interactions between the adenovirus penton base and integrin V 3","volume":"111","author":"Veesler","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.xcrm.2022.100658_bib94","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsb.2005.03.010","article-title":"Automated molecular microscopy: the new Leginon system","volume":"151","author":"Suloway","year":"2005","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.xcrm.2022.100658_bib95","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4169","article-title":"cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination","volume":"14","author":"Punjani","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2022.100658_bib96","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsb.2009.01.002","article-title":"Appion: an integrated, database-driven pipeline to facilitate EM image processing","volume":"166","author":"Lander","year":"2009","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.xcrm.2022.100658_bib97","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1047-8477(03)00069-8","article-title":"Accurate determination of local defocus and specimen tilt in electron microscopy","volume":"142","author":"Mindell","year":"2003","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.xcrm.2022.100658_bib98","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jsb.2009.01.004","article-title":"DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy","volume":"166","author":"Voss","year":"2009","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.xcrm.2022.100658_bib99","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1006\/jsbi.1999.4174","article-title":"EMAN: semiautomated software for high-resolution single-particle reconstructions","volume":"128","author":"Ludtke","year":"1999","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.xcrm.2022.100658_bib100","doi-asserted-by":"crossref","first-page":"e18722","DOI":"10.7554\/eLife.18722","article-title":"Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2","volume":"5","author":"Kimanius","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.xcrm.2022.100658_bib101","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jmb.2011.11.010","article-title":"A Bayesian view on cryo-EM structure determination","volume":"415","author":"Scheres","year":"2012","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.xcrm.2022.100658_bib102","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jsb.2012.09.006","article-title":"RELION: implementation of a Bayesian approach to cryo-EM structure determination","volume":"180","author":"Scheres","year":"2012","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.xcrm.2022.100658_bib103","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci."},{"key":"10.1016\/j.xcrm.2022.100658_bib104","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1038\/cti.2016.63","article-title":"A structure-function approach to optimizing TLR4 ligands for human vaccines","volume":"5","author":"Carter","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.xcrm.2022.100658_bib105","doi-asserted-by":"crossref","first-page":"15036","DOI":"10.1073\/pnas.232381299","article-title":"Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection","volume":"99","author":"Neuhierl","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.xcrm.2022.100658_bib106","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1128\/JCM.37.1.132-136.1999","article-title":"Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay","volume":"37","author":"Kimura","year":"1999","journal-title":"J.\u00a0Clin. Microbiol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122001902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122001902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:52:15Z","timestamp":1762987935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379122001902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666379122001902"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100658","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.17.480914","asserted-by":"object"}]},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunization with a self-assembling nanoparticle vaccine displaying EBV gH\/gL protects humanized mice against lethal viral challenge","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100658"}}